Description General description A cell-permeable benzothiazole compound that potently inhibits glutamate release and blocks Na+ channels. Reported to function as a polyglutamine aggregation inhibitor and stimulate the synthesis of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF) in mouse astrocyte cultures. Offers neuroprotection, slows disease progression in amyotrophic lateral sclerosis (ALS) patients, and prolongs survival in animal models of Huntington′s disease (HD). A cell-permeable benzothiazole compound that potently inhibits glutamate release and blocks Na+ channels. Shown to function as a polyglutamine aggregation inhibitor and stimulates the synthesis of NGF, BDNF, and GDNF in mouse astrocyte cultures. Reported to offer neuroprotection, slow down disease progression in ALS (amyotrophic lateral sclerosis) patients, and prolong the lifespan of animal models of HD (Huntington’s disease). Packaging 50 mg in Alu drum Biochem/physiol Actions Cell permeable: yes Primary Target Inhibits glutamate release and blocks Na+ channels Product does not compete with ATP. Reversible: no Packaging Packaged under inert gas Warning Toxicity: Toxic (F) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges. Heiser, V., et al. 2002. Proc. Natl. Acad. Sci. USA99, 16400. Schiefer, J., et al. 2002. Mov. Disord.17, 748. Mizuta, I., et al. 2001. Neurosci. Lett.310, 117. Louvel, E., et al. 1997. Trends Pharmacol. Sci.18, 196. Mizoule, J., et al. 1985. Neuropharmacology24, 767.